Form D · Biotechnology

Tarsa Therapeutics, Inc.

Philadelphia, PA · CIK 0001475030

Offering snapshot reported Jul 24, 2017 · SEC filing

Reported sold
$550K
Offering amount: $1M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 7, 2017
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 24, 2017Initial$549,858No comparison3SEC filing
Jan 13, 2017Initial$1,635,967No comparison5SEC filing
Jul 14, 2016Initial$1,250,000No comparison7SEC filing
Feb 19, 2016Initial$2,000,000No comparison7SEC filing
Mar 22, 2012Initial$13,767,857No comparison5SEC filing
Apr 21, 2011Amendment$15,500,000$12,000,000vs Oct 8, 20107SEC filing
Oct 8, 2010Initial$3,500,000No comparison5SEC filing
Oct 27, 2009Initial$12,050,000No comparison5SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-291370

Source: Form D, filed Jul 24, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Eric Bednarski Director
David Brand Director, Executive
Martin Edwards Director
Derek Ferguson Director
Lewis Geffen Executive
Richard Kollender Director
Richard Levy Director
Gregory Lumpkin Executive
Ashleigh Palmer Director
Matthew Rieke Director
James Tananbaum Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
8 Penn Center 1628 Jfk Blvd. Suite 1400
Philadelphia, PA, 19103